Dernières nouvelles pour Guardant Health (NASDAQ:GH) Stock

Guardant Health

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Guardant Health Inc

Gresham Technologies PLC

Grand Havana Inc

Glass House Brands Inc Warrants (15/01/2026)

Glass House Brands Inc

Graham Holdings Co

Galaxy Heroes Coin

Collaborative Investment Series Trust Goose Hollow Hedged Equity ETF

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

GreenTree Hospitality Group Ltd

GUANHUA CORPORATION by GuanHua Corporation

GuanHua Corp

Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests

Greystone Housing Impact Investors LP

Gamehost Inc

GREEN AND HILL INDUS INC by Green and Hill Industries, Inc.

Green and Hill Industries Inc

Gores Holdings IX Inc Ordinary Shares - Class A

Gores Holdings IX Inc

Gores Holdings IX Inc Units (1 Ord Class A & 1/3 War)

Gores Holdings IX Inc Warrants (31/01/2027)

Greenhill & Co Inc Com

Guild Holdings Company Class A Common Stock

Guild Holdings Co

Graham Corp

Accredited Solutions Inc

Collaborative Investment Series Trust Goose Hollow Multi-Strategy Income ETF

GHO - United States Dollar

Ghost

GOLD HUNTER RES INC by GOLD HUNTER RES INC

Gold Hunter Resources Inc

GOLDEN HORSE MINERALS LTD by GOLDEN HORSE MINERALS LTD

Golden Horse Minerals Ltd

GH Research PLC

GREENHEART GOLD INC by GREENHEART GOLD INC.

Guardion Health Sciences Inc

GHST World Inc

Aavegotchi - United States Dollar

Goose Hollow Tactical Allocation ETF

G-H-3 INTERNATIONAL INC by G-H-3 International, Inc.

G-H-3 International Inc

GoldHaven Resources Corp Ordinary Shares

GOLDHAVEN RESOURCES CORP by GoldHaven Resources Corp

GoldHaven Resources Corp

GamerCoin

PGIM Global High Yield Fund, Inc

Goldman Sachs Access High Yield Corporate Bond ETF

iShares US & Intl High Yield Corp Bond ETF

GOLD HYDROGEN LIMITED by Gold Hydrogen Limited

Gold Hydrogen Ltd

Earnings

Earnings Beats

Earnings Misses

News

TE Connectivity Q1 2025 Adj. EPS $1.95 Beats $1.89 Estimate, Sales $3.836B Miss $3.905B Estimate

Certain law enforcement officials from California are seemingly impressed by Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) vehicles customized for police use by vehicle customizer Unplugged Performance. 
What Happened: Unplugged Performance in December held an event where law enforcement executives tried out the <a href="https://www.benzinga.com/top-stories/24/04/38257550/tesla-model-y-enters-anaheim-police-fleet-in-new-pilot-initiative">Tesla vehicles upgraded</a> by the company. 
The officials drove the Tesla vehicles around at an EVOC facility and also compared it to a Ford Explorer PIU (Police Interceptor Utility SUV) with some concluding that the Tesla is way more fun to drive than the Explorer. 
Feedback From Law Enforcement Officials:&nbsp;&#8220;I think the difference between the two vehicles is just absolutely staggering. So after doing roughly you know 20/30 laps in the Tesla handling that course and then I jumped in the Explorer, did the same course, and I can tell you right off the bat I pretty much didn&#8217;t want to be in the Explorer anymore,&#8221; one of the officers said in the video premiered on YouTube on Tuesday.
An official, who had previously never driven a Tesla, said that the experience changed his perspective positively.
&#8220;I&#8217;d never driven one until today and I have a different mindset here at 2 p.m. than I did this morning at 6 a.m.,&#8221; he said. 
Why It Matters: Unplugged Performance,<a href="https://www.benzinga.com/news/24/06/39240046/tesla-customizer-upfits-cybertruck-for-the-police-forces-elon-musk-thinks-its-cool"> based out of California</a>, has been enhancing Tesla vehicles since 2013 and is located next to the company's design studio. 
According to Unplugged Performance, an upgraded Model Y AWD Patrol vehicle will cost $92,580, including upfitting costs, marginally higher than the Ford Police Interceptor Utility AWD Hybrid priced at $89,600. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Can UP.FIT Tesla Vehicles Handle Police Duty? This EVOC Trial Might Change Your Mind." width="500" height="281" src="https://www.youtube.com/embed/jaRObrWstTc?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43090016/which-evs-might-lose-7500-ev-tax-credit-under-trump-administration" target="_blank" rel="noreferrer noopener">Here Are The EVs Which Could Lose $7,500 EV Tax Credit Under Trump Administration</a></li>
</ul>
Image via Shutterstock

Tech

TSLA

California Law Enforcement Impressed By Upfitted Tesla Police Vehicle: 'I Pretty Much Didn't Want To Be In The Explorer Anymore'

Headquartered in San Mateo, Calif., QuSecure is a privately held company founded in 2019.&nbsp;

Accenture Reveals Strategic Investment, Through Accenture Ventures, In Post-quantum Cybersecurity Company QuSecure; Terms Not Disclosed

Barclays analyst Benjamin Theurer upgrades Hormel Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRL#NYSE">HRL</a>) from Equal-Weight to Overweight and raises the price target from $35 to $36.

Upgrades

Price Target

Analyst Ratings

Barclays Upgrades Hormel Foods to Overweight, Raises Price Target to $36

Barclays analyst Kannan Venkateshwar upgrades Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from Underweight to Equal-Weight and raises the price target from $715 to $900.

NFLX

Barclays Upgrades Netflix to Equal-Weight, Raises Price Target to $900

German sportswear brand Adidas AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ADDYY#OTC">ADDYY</a>) has released its <a target="_blank" href="https://www.adidas-group.com/en/media/press-releases/adidas-finishes-successful-year-with-better-than-expected-fourth-quarter-results" rel="noreferrer noopener">preliminary </a>results for the fourth quarter of 2024.
The company&#8217;s revenue increased by 19% in currency-neutral terms, with a 24% rise in euro terms, totaling 5.97 billion euros (~$6.24 billion). Excluding <a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38511886/adidas-puts-yeezy-history-behind-rides-fashion-high-with-samba-and-gazelle-shoes" rel="noreferrer noopener">Yeezy sales from both years</a>, currency-neutral growth was 18%.
Additionally, the company saw a notable improvement in its gross margin, which grew by 520 basis points to 49.8%, up from 44.6% in 2023.
Fourth-quarter operating profit reached 57 million euros, reversing the 377 million euros loss recorded in the same quarter last year.
Adidas also posted strong growth for the full year 2024. Its revenue climbed 12% on a currency-neutral basis, reaching 23.68 billion euros. When excluding Yeezy sales, the company saw a 13% increase in currency-neutral revenues.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/01/43098100/costco-workers-vote-to-strike-over-fair-contract-demands" rel="noreferrer noopener">Costco Workers Vote To Strike Over Fair Contract Demands</a>
The gross margin for the year improved by 330 basis points, reaching 50.8%. Operating profit surged by over 1 billion euros, rising from 268 million euros in 2023 to 1.34 billion euros in 2024.
&#8220;We clearly see that consumers&#8217; and retailers&#8217; interest in our products is growing across both Lifestyle and Performance. Strong growth across all regions and divisions proves the good job our teams are doing across regions and functions,&#8221; said CEO Bjørn Gulden.
&#8220;We also feel good about the future, and we see potential to increase our market share in all markets. There is a lot of macroeconomic uncertainty right now, but we clearly have the goal to again grow double-digit with the adidas brand and use that growth to continue to improve our operating profit and make further progress towards our 10% margin target.&#8221;
Price Action: ADDYY shares closed higher by 6.59% at $132.22 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43108106/volkswagen-warns-of-tariffs-impact-on-us-consumers" target="_blank" rel="noreferrer noopener">Volkswagen &#8216;Concerned&#8217; Over Trump Tariffs: Will Automakers Pass Costs To US Consumers?</a></li>
</ul>
Image via Shutterstock.

Equities

Guidance

General

ADDYY

Adidas Sees Solid Gains In Q4, Looks To Expand Market Share

Barclays analyst Simon Coles downgrades STMicroelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) from Equal-Weight to Underweight.

Downgrades

Barclays Downgrades STMicroelectronics to Underweight

JP Morgan analyst Mark Murphy downgrades Paycor HCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>) from Neutral to Underweight and raises the price target from $21 to $22.5.

PYCR

JP Morgan Downgrades Paycor HCM to Underweight, Raises Price Target to $22.5

JP Morgan analyst James Kirby initiates coverage on Sun Country Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCY#NASDAQ">SNCY</a>) with a Overweight rating and announces Price Target of $23.

Initiation

SNCY

JP Morgan Initiates Coverage On Sun Country Airlines with Overweight Rating, Announces Price Target of $23

JP Morgan analyst DS Kim downgrades New Oriental Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) from Overweight to Neutral and lowers the price target from $85 to $50.

New Oriental Education & Technology Group

JP Morgan Downgrades New Oriental Education to Neutral, Lowers Price Target to $50

Tesla Inc. CEO Elon Musk cast doubt Wednesday on the ambitious $500 billion Project Stargate, hours after its announcement, claiming lead investor SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) has &#8220;well under $10B secured.&#8221;
What Happened: The project, unveiled Tuesday at a White House briefing in the presence of President Donald Trump, represents a joint venture between OpenAI, SoftBank, and Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) to establish massive <a href="https://www.benzinga.com/25/01/43111153/nvidia-and-ai-stock-rises-as-trump-announces-500-billion-stargate-ai-infrastructure-venture">artificial intelligence infrastructure across the United States</a>. 
&#8220;They don't actually have the money,&#8221; Musk said.
&#8220;SoftBank has well under $10B secured. I have that on good authority.&#8221;
During the briefing, Oracle co-founder Larry Ellison highlighted the project&#8217;s healthcare applications, including an AI-driven system capable of delivering personalized cancer vaccines within 48 hours. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">SoftBank has well under $10B secured. I have that on good authority.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1881944244480565497?ref_src=twsrc%5Etfw">January 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/biotech/25/01/43119814/google-parent-owned-startup-to-launch-ai-designed-drug-trials-by-year-end-partnering-with-eli-lilly-and-novartis-to-tackle-major-diseases">Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases</a>
Why It Matters: The initiative plans to deploy an initial $100 billion immediately, starting with a 500,000-square-foot data center in Abilene, Texas. Nine additional facilities are planned, with potential expansion to 20 locations.
Technology partners Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), and Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) saw their stocks climb on the news. NVIDIA rose 3.95% to $143.15, while Arm jumped 8.94% to $162.60.
OpenAI, maintaining operational responsibility while SoftBank leads financial aspects, stated the project &#8220;will secure American leadership in AI&#8221; and &#8220;create hundreds of thousands of American jobs.&#8221; SoftBank&#8217;s Masayoshi Son will serve as chairman.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/43119464/netflix-raises-prices-16-peter-schiff-warns-of-escalating-inflation-risks-ahead-of-trump-policies">Netflix Raises Prices 16%, Peter Schiff Warns Of Escalating Inflation Risks Ahead Of Trump Policies</a></li>
</ul>
Image via Wikimedia Commons
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

MSFT

NVDA

ORCL

SFTBF

SFTBY

Elon Musk Says Project Stargate Doesn't 'Actually Have The Money' After Trump Announces $500 Billion AI Investment Led By SoftBank, Oracle And OpenAI

Jefferies analyst Dennis Ding upgrades Crinetics Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>) from Hold to Buy and announces $55 price target.

CRNX

Jefferies Upgrades Crinetics Pharmaceuticals to Buy, Announces $55 Price Target

Canaccord Genuity analyst Caitlin Burrows initiates coverage on Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Buy rating and announces Price Target of $24.

OFIX

Canaccord Genuity Initiates Coverage On Orthofix Medical with Buy Rating, Announces Price Target of $24

Canaccord Genuity analyst Maria Ripps upgrades Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from Hold to Buy and raises the price target from $940 to $1150.

Canaccord Genuity Upgrades Netflix to Buy, Raises Price Target to $1150

HUIZ

Huize Stated That It Served Over 1.3 Million Families With More Than 12 Million Insurance Policies Facilitated And Assisted In Processing 160,800 Insurance Claims (+74.7% YoY) In 2024

Shares of Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) rose sharply in today's pre-market trading as the company reported stronger-than-expected <a href="https://www.benzinga.com/news/earnings/25/01/43114866/netflix-q4-earnings-record-subscribers-nfl-squid-game-push-past-highest-expectations">fourth-quarter financial results</a>.
Netflix reported it added 18.91 million paid subscribers in the fiscal quarter, up 15.9% year-over-year. The company said it sees full-year revenue of $43.5 billion to $44.5 billion, up $0.5 billion from the company's previous range
Netflix shares jumped 14.6% to $996.60 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>ImmunoPrecise Antibodies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>) gained 58.8% to $0.7833 in pre-market trading. ImmunoPrecise Antibodies recently launched its AI-powered pipeline of both optimized and new therapeutics.</li>
<li>New Era Helium, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEHC#NASDAQ">NEHC</a>) rose 42% to $3.89 in pre-market trading. New Era Helium recently announced a joint venture with Sharon AI to construct and develop a 250MW net-zero energy data center..</li>
<li>Cardio Diagnostics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) rose 40.2% to $0.8520 in pre-market trading after jumping around 15% on Tuesday.</li>
<li>Asset Entities Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) gained 25.7% to $1.13 in pre-market trading after jumping 94% on Tuesday.</li>
<li>U.S. Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) gained 21.5% to $4.61 in pre-market trading after surging 63% on Tuesday.</li>
<li>Metagenomi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) gained 20.2% to $3.27 in pre-market trading following a 4% gain on Tuesday.</li>
<li>Tempus AI, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) gained 14.7% to $54.65 in pre-market trading. Tempus AI shares jumped over 35% on Tuesday after Nancy Pelosi disclosed the purchase of 50 Jan 2026 call options.</li>
<li>CareCloud, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) gained 13.3% to $3.50 in pre-market trading after surging over 10% on Tuesday.</li>
<li>Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) gained 13.2% to $29.63 in pre-market trading after gaining around 7% on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Associated Capital Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AC#NYSE">AC</a>) fell 43.7% to $20.00 in pre-market trading. Associated Capital recently reported estimated fourth quarter and full year results</li>
<li>Star Fashion Culture Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STFS#NASDAQ">STFS</a>) shares fell 20.7% to $10.72 in pre-market trading after dipping around 9% on Tuesday.</li>
<li>HUB Cyber Security Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBC#NASDAQ">HUBC</a>) fell 19.5% to $0.68 in pre-market trading after the company announced the receipt of a Staff Delisting Notice.</li>
<li>Lisata Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>) shares dipped 17.4% to $3.22 in pre-market trading after gaining 5% on Tuesday.</li>
<li>Septerna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) fell 14.4% to $16.01 in pre-market trading after gaining more than 10% on Tuesday.</li>
<li>Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares tumbled 13.1% to $0.8949 in pre-market trading after the company announced exercise of warrants and issuance of new warrants in a private placement for $3.7 million gross proceeds priced at-the-market.</li>
<li>Dogwood Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares fell 13% to $2.74 in pre-market trading. Dogwood Therapeutics shares jumped 68% on Tuesday after the company announced patient dosing for its Phase 2b trial evaluating halneuron will commence in Q1 2025.</li>
<li>AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) declined 12.3% to $14.81 in pre-market trading after gaining over 6% on Tuesday.</li>
<li>InMed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) fell 11.8% to $4.45 in today's pre-market trading. InMed Pharmaceuticals recently announced that INM-901 reduced Alzheimer &#8216;s-related inflammation in a preclinical study.</li>
<li>Marine Products Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPX#NYSE">MPX</a>) dipped 11.3% to $8.04 in pre-market trading. Marine Products will release its financial results for the fourth quarter on Thursday, Jan. 30, before the market opens.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>

Pre-Market Outlook

Movers

Trading Ideas

ANAB

ASST

CCLD

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

DWTX

HSDT

HUBC

LSTA

NEHC

SEPN

STFS

USEG

Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

On Tuesday, Cathie Wood-led Ark Invest made significant trades involving Accolade Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>), Deere &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>), Intellia Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>), Cameco Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>), Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>), Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Elbit Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>), and Absci Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>).
The trades include defense and energy companies, which have been in focus since the inauguration of Donald Trump. The President signed orders on Monday aimed at making it cheaper for companies to produce oil and gas, which could have an impact on energy companies. Defense stocks have also been in focus due to expectations of a pro-Israel stance from the new administration.
The NTLA Trade
The Ark Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and Ark Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) collectively purchased 91,889 shares of Intellia Therapeutics Inc. Based on the closing price of $9.94, the total value of the trade amounts to approximately $913,580.06. This move indicates Ark&#8217;s continued confidence in the gene-editing sector.
The PATH Trade
Ark Invest sold 21,879 shares of UiPath Inc. through its ARKK fund. Given the closing price of $13.33, the trade is valued at around $291,712.07. This sale suggests a shift in Ark&#8217;s stance on the automation software company.
The DE Trade
Ark Invest&#8217;s ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>) and ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) purchased a total of 3,474 shares of Deere &amp; Co. With the closing price at $463.15, the trade is worth approximately $1,607,571.10.
The CCJ Trade
Ark Invest also bought 17,504 shares of Cameco Corp (CCJ) through its ARKQ fund, valued at approximately $937,589.44 at the closing price of $53.56.
Other Key Trades:
<ul>
<li>Oklo Inc: Ark Invest sold 50333 shares through ARKQ.</li>
<li>Elbit Systems: Ark Invest Sold 2074 shares through ARKQ and 627 shares through ARKX.</li>
<li>Illumina Inc: Ark Invest bought 15876 shares through ARKG.</li>
<li>Absci Corp: Ark Invest bought 79411 shares through ARKG.</li>
<li>Accolade Inc: Ark Invest sold 466,337 shares through ARKG.</li>
</ul>
Photo courtesy: Ark Invest

ABSI

ACCD

ARKG

ARKK

ARKQ

ARKX

ESLT

ILMN

NTLA

OKLO

PATH

Cathie Wood's Ark Invest Buys Into Defense And Energy Stocks Amid Trump's Inaugural Policies

Shares of Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) experienced a 15% surge in premarket trading on Wednesday on the heels of the company announcing a 16%<a href="https://www.benzinga.com/markets/equities/25/01/43119464/netflix-raises-prices-16-peter-schiff-warns-of-escalating-inflation-risks-ahead-of-trump-policies" target="_blank" rel="noreferrer noopener"> price hike for its standard streaming plan.</a>
What Happened: Netflix&#8217;s shares saw an increase of $128.14 in the premarket, following a 1.35% rise at the close of the previous day, ending at $869.68. 
The price increase, which took the&nbsp;ad-free standard plan from $15.49&nbsp;to $17.99 per month, was announced in conjunction with Netflix&#8217;s impressive fourth-quarter earnings report.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/25/01/43118941/oracles-larry-ellison-says-cancer-vaccine-tailored-in-48-hours-could-soon-be-a-reality-as-trump-announces-500-billion-ai-investment" target="_blank" rel="noreferrer noopener">Oracle's Larry Ellison Says Cancer Vaccine Tailored In 48 Hours Could Soon Be A Reality As Trump Announces $500 Billion AI Investment</a>
The earnings report highlighted a 16% year-over-year revenue growth, reaching $10.25 billion, and a subscriber increase of 18.91 million. This surge in subscribers brought the total number of paid memberships to a staggering 301.63 million. The price increase also impacted the premium tier, now priced at $24.99, and the ad-supported option, which rose to $7.99.
Netflix&#8217;s robust performance, marked by a <a href="https://www.benzinga.com/25/01/43114866/netflix-q4-earnings-highlights-nfl-squid-game-power-best-subscriber-growth-in-company-history">record operating income surpassing</a>&nbsp;$10 billion for fiscal 2024,&nbsp;suggests a promising future for the company. Netflix anticipates its 2025 revenue to fall&nbsp;between $43.5 billion and $44.5&nbsp;billion, indicating a 12-14% growth. This projection underscores Netflix&#8217;s relatively&nbsp;small current share of the&nbsp;estimated $650 billion market opportunity&nbsp;across its key regions.
The company&#8217;s strong performance, driven by popular shows like &#8216;Squid Game&#8217; and its NFL content, has led to a significant <a href="https://www.benzinga.com/25/01/43104552/youtube-vs-netflix-streamers-top-usage-leaderboard-in-december-sector-makes-more-gains-on-broadcast-and-cable">increase in its subscriber base.</a> The price hike, which is the largest in the company&#8217;s history, is a bold move that reflects Netflix&#8217;s confidence in its future growth and content offerings.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/43118598/warren-buffetts-pilot-co-exits-global-oil-trading-refocuses-on-us-operations-report" target="_blank" rel="noreferrer noopener">Warren Buffett's Pilot Co Exits Global Oil Trading, Refocuses On US Operations: Report</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock

Netflix Rises 15% In Wednesday Premarket As Streaming Giant Hikes Prices Following Record Subscriber Growth

LOGI

Logitech Announced Rally Board 65, An All-in-one Portable Video Conference Solution That Combines Intelligent Audio And Video With A 65" Touchscreen Display

Logitech Introduced Logitech Spot, A Workplace Occupancy And Environmental Sensor That's Simple To Deploy In Nearly Any Space

Guardant Health announces prelim Q4 revenue above estimate

An announcement from Guardant Health ( ($GH) ) is now available. Guardant Health announced its preliminary, unaudited results for the fourth quarte...

Guardant Health Reports Revenue Growth Amid Cash Flow Losses

Stifel Nicolaus analyst Daniel Arias has maintained their bullish stance on GH stock, giving a Buy rating yesterday. Daniel Arias has given his Buy...

Guardant Health: Strong Financial Performance and Growth Potential Justify Buy Rating

In a report released yesterday, Michael Ryskin from Bank of America Securities maintained a Buy rating on Guardant Health (GH – Research Report), w...

Guardant Health: Strong Financial Performance and Market Leadership Bolster Buy Rating

Guardant Health (GH) announced a collaboration agreement that allows biopharmaceutical companies to access the first multi-modal real-world data RW...

Guardant Health, ConcertAI team for RWD that integrates EMR data for cancer care

Guardant Health: Remains Risky Despite SHIELD's Early Success

Guardant Health (GH) announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program ...

Guardant Health: MolDX administrator grants coverage for Guardant Reveal

Guardant stock jumps 12% on Medicare coverage expansion

In a report released today, Mark Massaro from BTIG reiterated a Buy rating on Guardant Health (GH – Research Report), with a price target of $55.00...

Guardant Health's Strategic Milestones and Medicare Coverage Drive Buy Rating with $55 Price Target

BTIG raised the firm's price target on Guardant Health (GH) to $55 from $50 and keeps a Buy rating on the shares. The firm reiterated Guardant as a...

Guardant Health price target raised to $55 from $50 at BTIG

Press Releases

Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium

Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer

COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics

Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care

Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute's Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results

Viz.ai to Collaborate With Guardant Health to Improve Lung Cancer Detection, Diagnosis, and Treatment

Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development

Guardant Health Receives Medicare Coverage for Guardant Reveal™ on Smart Liquid Biopsy™ Platform for Surveillance Testing in Colorectal Cancer Patients

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Guardant Health

Actualités

Dernières nouvelles pour Guardant Health (NASDAQ:GH) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL